Shop - SOFHET-V

Description

ACTIVE INGREDIENT : SOFOSBUVIR400 MG & VELPATASVIR100 MG
DESCRIPTION : SOFOSBUVIR-VELPATASVIR IS A PANGENOTYPIC NS5A-NS5B INHIBITOR SINGLE-PILL COMBINATION REGIMEN THAT HAS POTENT ACTIVITY AGAINST HEPATITIS C VIRUS (HCV) GENOTYPES 1, 2, 3, 4, 5, AND 6. IT PROVIDES A MUCH-NEEDED OPTION FOR PATIENTS WITH HCV GENOTYPE 3 INFECTION, INCLUDING THOSE WITH COMPENSATED CIRRHOSIS. NOTABLY, AN ABBREVIATED DURATION OF 8 WEEKS HAS NOT BEEN STUDIED WITH SOFOSBUVIR-VELPATASVIR FOR ANY OF THE GENOTYPES, EXCEPT IN CONJUNCTION WITH A THIRD AGENT (VOXILAPREVIR). SOFOSBUVIR-VELPATASVIR, LIKE LEDIPASVIR-SOFOSBUVIR, MAY HAVE HAVE LEVELS SIGNIFICANTLY REDUCED WITH ACID-REDUCING AGENTS, PARTICULARLY PROTON-PUMP INHIBITORS.